Long-Term Androgen Deprivation Better Than Short-Term in Prostate Cancer
the Cancer Therapy Advisor take:
Two years of adjuvant androgen deprivation therapy (ADT) combined with high-dose radiotherapy improves control and overall survival in high-risk patients with prostate cancer compared to short-term ADT, according to a recent study published in The Lancet Oncology.
Spanish researchers led by Almudena Zapatero, PhD, of the Hospital Universitario de la Princesa conducted an open-label, multicenter, phase 3 randomized controlled trial from November 2005 to December 2010. They examined 178 patients with prostate cancer who received short-term ADT and 177 who received long-term ADT.
Median follow-up was 63 months, and the primary endpoint was biochemical disease-free survival.
The researchers found that 5-year biochemical disease-free survival, 5-year overall survival and 5-year metastasis-free survival were all significantly better in patients who received long-term ADT compared to short-term.
Additionally, they found that the effect of long-term ADT on survival was more evident in patients with high-risk disease compared to low-risk patients.
Two years of adjuvant ADT combined with high-dose radiotherapy improves survival in prostate cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes
- Ponatinib Tops Bosutinib for Third-Line Treatment of CML in a Comparative Analysis
- Duvelisib Delayed Progression in CLL/SLL: Study
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Potential Diagnostic Tool Detects BCR-ABL1 mRNA in Chronic Myeloid Leukemia
- BTK Inhibitor Zanubrutinib Appears Promising in Waldenström Macroglobulinemia
- Carfilzomib Regimens Offer a Neuropathy-Sparing Approach in Multiple Myeloma, WM
- Apalutamide Does Not Diminish Quality of Life in Nonmetastatic Castration-Resistant Prostate Cancer
- Treatment Delays May Mean Worse Survival in Head and Neck Cancer